Advertisement
Advertise here Publish your press releases here Sponsor BioPortfolio
Follow us on Twitter Sign up for daily news and research emails Contributors wanted

Search Results for "Brilinta Sales"

12:06 EDT 20th April 2014 | BioPortfolio

Original Source: Brilinta (TM) - ticagrelor, AstraZeneca's new heart drug

Brilinta - ticagrelor, AstraZeneca's new heart drug is a blood-thinning medicine designed to prevent dangerous blood clots in patients with serious chest pain or previous heart attacks. It reduces the clumping of blood particles, called platelets,...

Matching Channels

Brilinta (TM) - ticagrelor, AstraZeneca's new heart drug

Brilinta - ticagrelor, AstraZeneca's new heart drug is a blood-thinning medicine designed to prevent dangerous blood clots in patients with serious chest pain or previous heart attacks. It re...

Sales Jobs

Pfizer

Pfizer is a global pharmaceutical company, the largest in world based on annual sales.  In 2009, annual sales were worth $45,448m. Pfizer spend £550m on R&D in the UK alone, and have...

Boehringer Ingelheim

Boehringer Ingelheim is a global pharmaceutical company with annual sales of over $16 billion, making it the 10th largest pharmaceutical company in the world based on sales.  With bases in 47 c...

Plavix

Plavix is a clot-busting drug, produced by Bristol-Myers Squibb Company, and reached annual sales in 2009 of $4.2m, making the third highest drug in the world (based on 2009 annual sales). Prescri...

Matching News

AstraZeneca Makes Progress on Global Brilinta Trial

AstraZeneca announced it has completed patient enrollment approximately four months ahead of plan in the Phase 3 clinical trial EUCLID studying Brilinta (ticagrelor) table

Pascal pushes AZ to push Brilinta in diabetes

Speaking on 3 December at the FT Global Pharmaceuticals and Biotechnology Conference in London, Dr Soriot repeated his finger-pinpointing at poor marketing at AstraZeneca as the cause of Brilinta's un...

A TRANSPARENT CORRECTION: Pascal pushes AZ to push Brilinta in diabetes

Speaking on 3 December at the FT Global Pharmaceuticals and Biotechnology Conference in London, Dr Soriot repeated his finger-pinpointing at poor marketing at AstraZeneca as the cause of Brilinta's un...

Brilinta: Phase III started

Brilinta: Completed Phase IIIb enrollment

UPDATE 1-AstraZeneca earnings heading south as patent losses bite

* Brilinta experienced headwinds after U.S. investigation

Doctor Challenges AstraZeneca Drug

AstraZeneca's anticlotting drug Brilinta was approved based on a study showing the pill saved lives and reduced heart attacks. But a drama is unfolding over whether the drug should have been approved.

AstraZeneca Says Revamped Pipeline Will Return It To Health, But Pitfalls Remain

Equipped with 19 drug candidates for Phase III trials over the next two years, Britain’s AstraZeneca says it’s finally “on a roll.” But the troubled medicine maker still expects earnings to ke...

Matching PubMed Articles

Sellers, shakers, peddlers, and hawkers: rehabilitation of sales workers.

Sales workers persuade, influence, inform and cajole customers, resulting in the purchase of a product or service. The selling profession is broken down into three categories: sales technology, genera...

The effect of consignment to broodmare Sales on physiological stress measured by faecal glucocorticoid metabolites in pregnant Thoroughbred mares.

Validation of a method for the minimally-invasive measurement of physiological stress will help understanding of risk factors that may contribute to stress-associated events including recrudescence of...

Ariad suspends ponatinib sales.

Because of concerns about serious cardiovascular side effects, the U.S. Food and Drug Administration asked Ariad Pharmaceuticals to temporarily suspend sales and marketing of ponatinib to treat chroni...

Which Pharmaceutical Sales Representatives' Features do Slovenian Family Physicians Value?

One of the key strategies for marketing new drugs to physicians is personal selling by pharmaceutical sales representatives (PSRs).

Kidney Sales and the Analogy with Dangerous Employment.

Proponents of permitting living kidney sales often argue as follows. Many jobs involve significant risks; people are and should be free to take these risks in exchange for money; the risks involved in...

Search Whole site using Google

Loading
Search BioPortfolio:
Advertisement
Advertisement
Advertisement Advertisement